Abstract
Colorectal cancer is one of the major causes of cancer mortality in the elderly population (median age at diagnosis of 71 years) in Western Countries. Moreover patients with metastatic disease are often elderly with significant co- morbidities. Unfortunately, elderly patients are often untreated and under-represented in clinical trials, even if most clinical trials that have included this setting of population have shown similar survival rates and toxicities to younger patients.
Age itself should not be considered for candidacy to chemotherapy but it should be taken in consideration the great heterogeneity of co-morbidities present in the elderly population. Therefore, the best treatment strategy for elderly colorectal cancer patients has not yet been defined. Comprehensive Geriatric Assessment is recommended to evaluate the best strategy treatment and to reduce the adverse events. In fact, while fit elderly patients could receive the same therapeutic treatment as the younger counterpart, a palliative approach should be taken in consideration for frail elderly patients and for those with a short life expectancy.
Keywords: Elderly, colorectal, cancer, chemotherapy, treatment.
Anti-Cancer Agents in Medicinal Chemistry
Title:Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure
Volume: 13 Issue: 9
Author(s): Massimiliano Berretta, Fabrizio Di Benedetto, Raffaele Di Francia, Emanuele Lo Menzo, Sergio Palmeri, Umberto Tirelli and Paolo De Paoli
Affiliation:
Keywords: Elderly, colorectal, cancer, chemotherapy, treatment.
Abstract: Colorectal cancer is one of the major causes of cancer mortality in the elderly population (median age at diagnosis of 71 years) in Western Countries. Moreover patients with metastatic disease are often elderly with significant co- morbidities. Unfortunately, elderly patients are often untreated and under-represented in clinical trials, even if most clinical trials that have included this setting of population have shown similar survival rates and toxicities to younger patients.
Age itself should not be considered for candidacy to chemotherapy but it should be taken in consideration the great heterogeneity of co-morbidities present in the elderly population. Therefore, the best treatment strategy for elderly colorectal cancer patients has not yet been defined. Comprehensive Geriatric Assessment is recommended to evaluate the best strategy treatment and to reduce the adverse events. In fact, while fit elderly patients could receive the same therapeutic treatment as the younger counterpart, a palliative approach should be taken in consideration for frail elderly patients and for those with a short life expectancy.
Export Options
About this article
Cite this article as:
Berretta Massimiliano, Benedetto Di Fabrizio, Francia Di Raffaele, Menzo Lo Emanuele, Palmeri Sergio, Tirelli Umberto and Paoli De Paolo, Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660350
DOI https://dx.doi.org/10.2174/18715206113136660350 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacophore Generation and 3D-QSAR of Novel 2-(quinazolin-4- ylamino)-[1,4] Benzoquinone Derivatives as VEGFR-2 Inhibitors
Letters in Drug Design & Discovery Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Diabetes Case Identification Methods Applied to Electronic Medical Record Systems: Their Use in HIV-Infected Patients
Current HIV Research The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Application of a Deep Matrix Factorization Model on Integrated Gene Expression Data
Current Bioinformatics The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Players in ADP-ribosylation: Readers and Erasers
Current Protein & Peptide Science Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued)